Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
01 oct. 2020 07h30 HE | Athira Pharma, Inc.
-Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer’s disease- SEATTLE, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...
Annovis_Corp_Image.png
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
29 sept. 2020 06h45 HE | Annovis Bio Inc.
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal...
logo-brainhq-hi-res-hori.png
Study: BrainHQ in Combination with Other Interventions Reduces Alzheimer’s Risk
10 sept. 2020 08h00 HE | Posit Science
SAN FRANCISCO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- A study from Australia, published today in the Journal of the American Geriatrics Society, found that an eight-week multimodal program — combining...
Dementia, brain research, residential care: Seniors issues poll strongly during COVID-19 pandemic
08 sept. 2020 09h30 HE | The Brain Project - Baycrest Foundation
TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- The well-being of Canadian seniors is in hyperfocus amid the COVID-19 pandemic, according to a new national survey by The Baycrest Foundation. The...
Logo-FullColour.png
Highmark Interactive Announces Partnership with PointClickCare, Integrating Game-Based Testing for Seniors’ Brain Health
30 juil. 2020 09h22 HE | Highmark Interactive
TORONTO, July 30, 2020 (GLOBE NEWSWIRE) -- Highmark Interactive, creators of the world’s first mobile, gamified, FDA cleared neurological assessment tool, is proud to announce its partnership with...
Annovis_Corp_Image.png
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
20 juil. 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
07 juil. 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Logo.jpg
Cutting Edge medical advancements in technology - MoviWearMed is geared to protect the most vulnerable population during Covid-19
19 juin 2020 08h00 HE | MoviWear
TORONTO, June 19, 2020 (GLOBE NEWSWIRE) -- Jacob Moshinsky, founder of MoviWear has once again created buzz, this time in the medical industry. MoviWearMed is a new medical platform that allows 24/7...
Annovis_Corp_Image.png
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
16 juin 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
02 juin 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...